Opinion|Videos|February 10, 2025
The Economic Impact of Biosimilars
Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Biosimilars have been shown to reduce costs to the US health system overall. What kind of savings are you seeing in your health system since fully implementing biosimilars?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
How MCOs Should Be Preparing for the OBBBA's Medicaid Cuts: David Brueggeman, MBA
5